× Unpublished This content is unpublished, click the edit tab and check "Published" on the bottom of the form. 27. 09.15 09:00 Close share menu New data from KEYNOTE-028, MSD's trial evaluating KEYTRUDA (pembrolizumab) across a range of cancer types, presented at 2015 European Cancer Congress Source FinanzNachrichten.de Close share menu